Skip to content Skip to footer
Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Shots:Post M&A deals, companies often cannot sail through a few key aspects of the partnership, such as limited ownership, exorbitant recovery costs, and poor integration process, leading to deal terminations. The improperly executed expansion program also contributes significantly to the failed partnershipTo tackle such scenarios, companies are cautious enough to make backup plans beforehand…

Read more

Disease of the Month: AIDS

Disease of the Month: AIDS

“Putting Ourselves to the Test: Achieving Equity to End HIV”  -Theme of the year 2022 Introduction:HIV/AIDS is one of the top 10 cause of mortality. It is a chronic, epidemic disease caused by human immunodeficiency virus (HIV), a virus that infect WBC’s CD4 T-cell of the immune system.HIV, a type of retrovirus that isn't…

Read more

Prescription Drugs Top 20 2019

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology- cardiology- and neurology but are they…

Read more